#Epclusa

Pairing HCV testing and treatment eliminates the need to navigate the medical system.

Sofosbuvir-based regimens were well tolerated and cure rates were high in this population.

The number of people treated for hepatitis C hit a low point during the COVID-19 pandemic.

People who received a shortened course of antiviral therapy were less likely to be cured.

Timely testing and treatment could improve outcomes for young people who inject drugs.

Louisiana saw a bump-up in HCV prescriptions after the alternate model was introduced.

The Epclusa and Mavyret combination pills are now indicated for kids as young as age 3.

With many hepatitis C treatments on the market today, patients may ask which hepatitis C treatment is right for me? What’s the difference?

After inmates filed a class action lawsuit, Nevada agreed to treat all prisoners living with hepatitis C.

Despite limited testing and clinical visits, 95% of the study population was able to achieve a sustained virological response.

These recommendations are based on the World Health Organization’s guidelines.

Homeless people, incarcerated individuals and people with mental health conditions achieved a high cure rate.

The assurance arrives as the pharma giant cuts off most emergency access to remdesivir, a potential COVID-19 treatment.

Gilead Sciences’ direct-acting antiviral regimen was previously approved for adults.

Six weeks, compared with the standard 12 weeks, was associated with an unacceptably high rate of viral relapse.